VTGN Latest Press Releases

-- August 6, 2026 --

Vistagen Announces Topline Results for Repeat Dose Study of Fasedienol for Acute Treatment of Social Anxiety Disorder Globe Newswire 8:30 AM

-- August 4, 2026 --

SRX Global Acquires Stake in Vistagen Therapeutics (NASDAQ: VTGN) Globe Newswire 5:00 AM

-- July 31, 2026 --

Vistagen Appoints Douglas J. Williamson to its Board of Directors Globe Newswire 8:30 AM

-- June 30, 2026 --

Vistagen Announces Topline and Post-Hoc Data from PALISADE-4 Phase 3 Public Speaking Challenge Trial of Fasedienol for the Acute Treatment of Social Anxiety Disorder Business Wire 8:00 AM

-- June 15, 2026 --

Vistagen Reports Fiscal Year 2026 Financial Results and Provides Corporate Update Business Wire 4:30 PM

-- June 9, 2026 --

Vistagen Achieves Minimum ICH Safety Exposure Recommendations Across Clinical Program for Fasedienol for the Acute Treatment of Social Anxiety Disorder Business Wire 8:30 AM

-- June 1, 2026 --

Kuehn Law Encourages Investors of Vistagen Therapeutics, Inc. to Contact Law Firm PRNewswire 2:40 PM

-- May 27, 2026 --

Vistagen to Participate in Jefferies 2026 Global Healthcare Conference Business Wire 8:30 AM

-- May 19, 2026 --

Vistagen Appoints Angel S. Angelov, MD, MBA, as Chief Medical Officer Business Wire 8:30 AM

-- May 14, 2026 --

Vistagen to Participate in the 2026 RBC Capital Markets Global Healthcare Conference Business Wire 8:30 AM

-- May 12, 2026 --

Vistagen Announces Preliminary Positive Data in Ongoing Open-Label Extension Portion of PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Business Wire 7:30 AM

-- May 8, 2026 --

Vistagen Announces Completion of Last Patient Visit in PALISADE-4 Phase 3 Public Speaking Challenge Study of Fasedienol for Acute Treatment of Social Anxiety Disorder Business Wire 7:30 AM

-- April 29, 2026 --

Kuehn Law Encourages Investors of Vistagen Therapeutics, Inc. to Contact Law Firm Globe Newswire 3:12 PM

-- April 28, 2026 --

Vistagen Therapeutics, Inc. (NASDAQ: VTGN) Investor Alert: Schubert Jonckheer Investigating Possible False Claims Regarding Drug Candidate Following 80% Stock Drop PRNewswire 9:01 AM

-- April 22, 2026 --

Vistagen Receives FDA "Study May Proceed" Letter Under its Refisolone IND Application, Enabling Further Phase 2 Clinical Development for the Treatment of Vasomotor Symptoms (Hot Flashes) due to Menopause Business Wire 8:30 AM

-- March 17, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Vistagen Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - VTGN Globe Newswire 3:49 PM

-- March 16, 2026 --

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 16, 2026 in Vistagen Therapeutics, Inc. Lawsuit - VTGN Globe Newswire 4:00 PM

CLASS ACTION DEADLINE TONIGHT MONDAY, MARCH 16: Faruqi & Faruqi, LLP Reminds Vistagen Therapeutics Investors of the Securities Class Action Lawsuit Deadline Tonight Business Wire 11:09 AM

VTGN Deadline: VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit PRNewswire 5:00 AM

-- March 15, 2026 --

VTGN DEADLINE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Vistagen Therapeutics, Inc. Investors to Secure Counsel Before Important March 16 Deadline in Securities Class Action - VTGN Newsfile 10:16 PM

-- March 14, 2026 --

VTGN DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Vistagen Therapeutics, Inc. Investors to Secure Counsel Before Important March 16 Deadline in Securities Class Action - VTGN Globe Newswire 6:01 PM

-- March 13, 2026 --

VTGN DEADLINE: ROSEN, A TOP RANKED LAW FIRM, Encourages Vistagen Therapeutics, Inc. Investors to Secure Counsel Before Important March 16 Deadline in Securities Class Action - VTGN Newsfile 9:46 PM

VTGN DEADLINE: ROSEN, A TOP RANKED LAW FIRM, Encourages Vistagen Therapeutics, Inc. Investors to Secure Counsel Before Important March 16 Deadline in Securities Class Action - VTGN Globe Newswire 4:25 PM

VTGN Shareholder Alert: Vistagen Therapeutics, Inc. Securities Class Action Lawsuit Investors With Losses May Join - The Gross Law Firm Globe Newswire 9:00 AM

-- March 12, 2026 --

VTGN DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Vistagen Therapeutics, Inc. Investors to Secure Counsel Before Important March 16 Deadline in Securities Class Action - VTGN Newsfile 9:41 PM

Holzer & Holzer, LLC Reminds VTGN Investors of the March 16, 2026 Lead Plaintiff Deadline in the Vistagen Therapeutics, Inc. Securities Class Action Globe Newswire 4:54 PM

VTGN INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Vistagen Therapeutics (VTGN) Investors of Securities Class Action Deadline on March 16, 2026 Globe Newswire 9:10 AM

-- March 11, 2026 --

VTGN DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Vistagen Therapeutics, Inc. Investors to Secure Counsel Before Important March 16 Deadline in Securities Class Action - VTGN Newsfile 9:35 PM

VTGN SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Vistagen Therapeutics (VTGN) Investors of Securities Class Action Deadline on March 16, 2026 PRNewswire 9:01 AM

LEVI & KORSINSKY, LLP ADVISORY TO INSTITUTIONAL INVESTORS: CLASS ACTION AGAINST VISTAGEN THERAPEUTICS MAY IMPACT PORTFOLIO HOLDINGS PRNewswire 9:00 AM

Class Action Filed Against Vistagen Therapeutics, Inc. (VTGN) - March 16, 2026 Deadline to Join - Contact Levi & Korsinsky PRNewswire 9:00 AM